MSLE Overview

Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.

Wall Street analysts forecast MSLE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MSLE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Satellos Bioscience Inc revenue for the last quarter amounts to 0.00 USD, decreased

Satellos Bioscience Inc. EPS for the last quarter amounts to -0.53 USD, increased 20.45

Satellos Bioscience Inc (MSLE) has 18 emplpoyees as of June 18 2026.

Today MSLE has the market capitalization of 121.86M USD.